| Detected | Trial | Change |
|---|---|---|
| 2026-08-05 | NCT06476184 Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly… |
Trial sites expanded: 72 -> 76 locations |
| 2026-08-05 | NCT06476184 Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly… |
date change Completion moved earlier: 2028-12 -> 2028-06 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-08-13 | NCT07763496 Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06476184 | Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly… | Ovarian Cancer | Recruiting |
| NCT05201547 | Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First… | Endometrial Cancer | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT03651206 | Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib | Ovarian Carcinosarcoma | Recruiting |
| Phase 2 | |||
| NCT04602377 | Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT | Small Cell Ovarian Carcinoma | Recruiting |
| NCT05183984 | Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer | Ovarian Cancer | Recruiting |
| NCT04713514 | OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With… | Platinum-sensitive Ovarian Cancer | Active, Not Recruiting |
| NCT06715241 | A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND… | LOCALLY ADVANCED CERVICAL CANCERS | Active, Not Recruiting |
| NCT07763496 | Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer | Recurrent or Metastatic Cervical Cancer | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT07637851 | Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer | Ovarian Cancer | Not Yet Recruiting |